Document Detail

TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves' disease patients.
MedLine Citation:
PMID:  19675869     Owner:  NLM     Status:  MEDLINE    
Antibodies to TSH receptors (TRAb) have great pathogenetic importance in the development and maintenance of hyperthyroidism in Graves' disease (GD). Measurement of their serum level could be of diagnostic and prognostic importance in autoimmune hyperthyroidism and in monitoring the efficiency of thyrosuppressive drug (TSD) treatment in GD. The aim of our study was to assess the sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) of the TRAb assay in confirming the diagnosis and to define its prognostic value for remission duration in GD patients at the end of TSD treatment with thionamide derivatives, propylthiouracil or methimazole. We studied 99 patients, 65 female, 34 male, 18-76 years old; 52 GD patients and 47 as control group. We have studied frequency of relapses and remission duration in GD patients by a 2nd generation serum TRAb commercial kit. Our results showed that, the SN, SP, PPV and NPV of the TRAb test were 100%, 97%, 98% and 100%, respectively. Remission duration after TSD treatment was longer and relapses were fewer in GD patients with lower levels of TRAb before (P<0.01) and at the end of TSD treatment (P<0.05). In conclusion, our results suggest that serum TRAb is very sensitive and specific for confirming the diagnosis of GD. TRAb levels at the beginning of TSD treatment, above 5 IU/L gives 18% greater chance, and above 15 IU/L, 36% greater chance for remission, shorter than 6 months.
Aleksandar Aleksić; Zeljka Aleksić; Miodrag Stojanović
Related Documents :
7396599 - Clinical hyperthyroidism in a patient receiving long-term hemodialysis.
4042519 - Pharmacokinetic properties and bioavailability of methimazole.
3020879 - Thyroid function after postoperative radiation therapy in patients with breast cancer.
17601419 - Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral anti...
12741459 - Effect of hypo- and hyperthyroidism on gastric myoelectrical activity.
19549249 - Short-term overt hypothyroidism induces sympathovagal imbalance in thyroidectomized dif...
12747279 - Link between anti-cd36 antibodies and thrombosis in the antiphospholipid syndrome.
24452809 - Population pharmacokinetic modelling of recombinant factor ix fc fusion protein (rfixfc...
21829039 - Enhanced nitrosative and oxidative stress with decreased total antioxidant capacity in ...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Hellenic journal of nuclear medicine     Volume:  12     ISSN:  1790-5427     ISO Abbreviation:  Hell J Nucl Med     Publication Date:    2009 May-Aug
Date Detail:
Created Date:  2009-08-13     Completed Date:  2009-10-01     Revised Date:  2010-08-23    
Medline Journal Info:
Nlm Unique ID:  101257471     Medline TA:  Hell J Nucl Med     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  146-50     Citation Subset:  IM    
Health Center Zajecar, Nikole Pasića 88/3, 19 000 Zajecar, Serbia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Graves Disease
Immunoglobulins, Thyroid-Stimulating / diagnostic use*
Middle Aged
Radiopharmaceuticals / diagnostic use
Remission Induction
Reproducibility of Results
Sensitivity and Specificity
Technetium / diagnostic use*
Thyrotropin / therapeutic use*
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Immunoglobulins, Thyroid-Stimulating; 0/Radiopharmaceuticals; 0/thyrotropin-binding inhibitory immunoglobulin; 7440-26-8/Technetium; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Iotandium-111 pentetreotide scintigraphy and CT scans after 3 years in the follow-up of patients wit...
Next Document:  Can response to palliative treatment with radiopharmaceuticals be further enhanced?